Biotech Startups

Omeza is an ocean biotechnology company developing marine-based regenerative wound-care products, including its FDA-cleared OCM wound matrix made from cold-water fish peptides, omega fatty acids, and plant-derived lipids, to treat chronic, hard-to-heal wounds such as diabetic foot ulcers and venous leg ulcers in adults. The commercial-stage company serves the U.S. advanced wound care market and markets its products to clinical care sites.

1 investor

Omica develops precision oncology technology focused on the Latin American market, serving life sciences organizations and cancer centers.

1 investor

Datma provides a federated data collaboration platform connecting health systems and labs with pharmaceutical companies for secure access to real-world clinical and molecular data. The platform enables pharma teams to access complete, de-identified datasets while allowing health systems and labs to maintain data control and generate revenue.

1 investor

OmicsBank positions itself around phenotyped patient cohorts and omics data used to validate novel drug targets and stratify responders ahead of clinical trials. It references AI-discovered drug targets and biomarker analysis in the context of biotech drug development.

1 investor

OMIQ offers flow cytometry data analysis software, including AdaptiGate, a machine-learning autogating tool that adapts user-defined gates from a template file across all samples in a dataset. It serves researchers and organizations performing flow cytometry analysis in the life sciences.

1 investor

OmniAb develops transgenic animal platforms engineered to generate human antibodies for therapeutic drug discovery, serving biopharmaceutical researchers and drug developers.

1 investor

OmniActive develops scientifically validated, nature-based ingredients for the nutraceutical and natural products industry. The company specializes in extracting and delivering innovative ingredient solutions sourced from spices and natural materials.

1 investor

OmniBio develops biologically-inspired AI models for autonomous robots and machines used in manufacturing, agriculture, and construction. The technology enables robots to learn and adapt in dynamic environments without traditional sensors or connectivity.

1 investor

Omnicare is a German healthcare group focused on oncology, operating medical care centers (MVZ) with physicians and oncologists across multiple sites, clean-room laboratories, pharmaceutical wholesale, hygiene monitoring, and quality initiatives for pharmacies and oncology practices. It also runs psychosomatic clinics and provides software (eApo) and training for medical staff.

1 investor

OmniCyte is a biotechnology company developing vaccines and cancer immunotherapies, including a SARS-CoV-2 vaccine program and immune-response engineering work conducted in collaboration with academic medical centers. Its research focuses on recombinant vaccine development and immuno-oncology approaches.

1 investor

Omniose develops a platform for bioconjugate vaccine development using glycoconjugation technology to create vaccines against bacterial pathogens like Group B Streptococcus and Klebsiella pneumoniae. The company works with pharmaceutical and research partners to advance vaccine candidates through preclinical and clinical development.

1 investor

A biotech company developing a multi-layered polymer delivery system for sustained-release vaccine and medication administration via single injection.

1 investor

OmniTier develops on-premise genomics analysis software and systems that use efficient memory-leveraged computing to enable faster and more cost-effective multiomic data analysis compared to cloud-based approaches.

1 investor

Omos Biosciences develops molecular diagnostic tools that analyze the molecular signatures of pre-cancers to identify which cases are high risk and require intervention. The technology is aimed at helping clinicians with treatment stratification to reduce over-treatment and enable early cancer intervention.

1 investor

Order-made Medical Research Inc. (OMR) develops antibody drug discovery technologies, including its LIMAXYS platform for generating antibodies against multi-pass transmembrane targets, plus the INTAB and MUTAB platforms for internalizing and disease-specific mutation antibodies. The company aims to create new antibody-based therapies for hard-to-treat cancers, autoimmune diseases, and neurodegenerative disorders.

1 investor

OMX is a venture capital firm investing in life sciences and biotechnology companies across therapeutics, synthetic biology, and diagnostics. This page presents its portfolio companies rather than a product of its own.

1 investor

Onchilles Pharma is a biopharmaceutical company developing novel therapeutics based on scientific research to address unmet medical needs. The company is led by a team with academic and industry backgrounds in drug development.

1 investor

Oncobit provides molecular diagnostic solutions that enable clinicians to monitor cancer and optimize therapy selection through advanced genetic analysis of plasma samples.

1 investor

Oncobox provides low-cost personalized genetic profiling that analyzes tumor DNA, RNA, and molecular pathways to recommend which targeted drugs are likely most effective for an individual late-stage cancer patient. It serves doctors and partners from pharma, hospitals, payers, and genomic centers in oncology.

1 investor

Oncoclínicas operates a network of over 140 units — clinics, genomics and pathology laboratories, and integrated cancer treatment centers — across 40 Brazilian cities. It provides cancer diagnosis and treatment services for patients in Brazil.

1 investor

Oncocross is a South Korean precision medicine company that uses an AI platform built on multi-omics data, with business spanning drug discovery, diagnostics, and clinical applications. It offers LC/MS-based multi-omics analysis, a digital bio-bank of clinical and pathology data, and AI tools for cancer detection and drug indication discovery.

1 investor

OncoForma develops a functional precision oncology platform that tests patient-derived tumor organoids against comprehensive drug panels to predict treatment efficacy before therapy begins. The company serves oncologists and cancer patients in the global oncology market, operating from Saskatchewan with a pathway to scale from fee-for-service testing to AI-enabled predictive medicine.

1 investor

A clinical research organization that conducts clinical trials to provide innovative therapies to patients in specific medical conditions at no additional cost.

1 investor

Oncology Ventures is a cancer-focused venture capital fund that invests in healthcare technology startups related to oncology care. It backs companies across value-based oncology, digital health, and cancer treatment models.

1 investor